Sentio BioSciences

What Sentio BioSciences does

Sentio BioSciences LLC is a privately held, US-based specialty pharmaceutical company and Contract Development and Manufacturing Organization (CDMO) headquartered in Maryland Heights, Missouri. Founded in 2008 by Karthik Raghavan and Flavia D'Souza, the company operates over 22,000 sq ft of cGMP-compliant infrastructure, including 9+ ISO 7/8 certified clean room suites, dedicated suites for toxic and potent compound manufacturing, on-site Water-for-Injection production, and flow/continuous manufacturing capacity scaled from 10 g to 100 kg batches with annual capacity up to 5 metric tons. It is registered with the FDA (FEI 3007640515), the DEA as a Schedule II-V Researcher (RS0683359), and the EPA as a federal large generator of hazardous waste, and has passed biennial FDA inspections in good standing since 2015.

The company operates a dual business model. On the services side, it provides CDMO offerings spanning process development, clinical and commercial cGMP manufacturing of APIs and drug products (parenterals, tablets, capsules, emulsions), analytical method development and validation, stability testing, and regulatory filing support including DMF, IND, ANDA, and NADA submissions. On the products side, Sentio markets proprietary and generic pharmaceuticals — notably Pentosan Polysulfate Sodium (the only FDA-approved injectable pentosan for equine osteoarthritis), Diroban (melarsomine dihydrochloride, the first FDA-approved generic heartworm treatment for dogs), and a pipeline of preclinical candidates (SENT008, SENT012 for human osteoarthritis) plus six generic essential medicines (SENT005-SENT011) spanning urology, oncology, cardiovascular, and other essential indications.

Revenue is generated through B2B contract manufacturing fees, sales of proprietary and generic drug products, and licensing of innovation pipelines. Customer segments are predominantly enterprise pharmaceutical and biotech companies seeking US-based cGMP manufacturing, with named partners including Apertus Pharmaceuticals and the API Innovation Center (APIIC), the latter awarding a December 2024 contract for development of two critical APIs. In June 2025, Sentio announced a $10.6 million expansion at its Maryland Heights facility creating 58 new jobs, and in July 2025 it received the SHARP Award from the Missouri Department of Labor for workplace safety excellence. The company positions itself as a contributor to US pharmaceutical supply chain resilience for essential medicines, with no disclosed revenue, funding rounds, or institutional investors in the available data.

Name

Sentio BioSciences

Legal name

Sentio BioSciences LLC

Website

https://sentiobiosciences.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

11–50 employees

Short description

Sentio BioSciences is a US-based specialty pharmaceutical manufacturer and CDMO in Maryland Heights, Missouri, providing cGMP API and drug-product development, manufacturing, and regulatory services, alongside proprietary and generic medicines for human and animal health.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

akta.pro secondary industries

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Contract pharmaceutical manufacturing
• CGMP manufacturing services
• Small molecule APIs
• Essential medicines production
• Animal health therapeutics

Headquarters

HQ city

Maryland Heights

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. CDMO Services: Contract Development and Manufacturing Organization services offering development through approved commercial cGMP manufacturing for APIs and drug products. Services include process development, manufacturing, analytical services, regulatory support, and stability studies.
2. Essential Medicines Manufacturing: Manufacturing and commercialization of critical pharmaceuticals including generic essential medicines for human and animal health.
3. Proprietary Product Licensing: Innovation and licensing of breakthrough proprietary products including Pentosan Polysulfate Sodium for equine osteoarthritis and pipeline products SENT008 and SENT012 for human osteoarthritis.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Sentio BioSciences is a US-based cGMP manufacturer operating from a 22,000+ sq ft FDA-registered facility in Maryland Heights, Missouri, providing contract development and manufacturing organization (CDMO) services for small molecule APIs and drug products from process development through commercial manufacturing. The company also develops and commercializes its own portfolio of proprietary and generic pharmaceutical products for human and animal health, including FDA-approved Pentosan Polysulfate Sodium for equine osteoarthritis, Melarsomine Dihydrochloride (Diroban) for canine heartworm disease, and pipeline candidates SENT008 and SENT012 for human osteoarthritis along with six generic essential medicines in development.

Product overview

Sentio BioSciences is a specialty pharmaceutical company offering a dual business model: (1) Proprietary and generic pharmaceutical products for human and animal health, and (2) Contract Development and Manufacturing Organization (CDMO) services. The product portfolio includes Pentosan Polysulfate Sodium (FDA-approved equine osteoarthritis treatment), two proprietary candidates in preclinical development (SENT008 and SENT012 for osteoarthritis), and six generic essential medicines (SENT005-SENT011) covering urology, oncology, cardiovascular, and medically essential indications at various development stages. CDMO services span process development, cGMP manufacturing (10kg-100kg batch scale, up to 5MT annual capacity), analytical testing, and regulatory filings. The company operates advanced manufacturing capabilities including flow chemistry, continuous manufacturing, and high-potency/toxic substance handling with containment suites.

Differentiator

Problem solved

Functional benefit

Products and services

• Pentosan Polysulfate Sodium FDA-approved injectable Pentosan Polysulfate Sodium for the treatment of osteoarthritis in horses; the only FDA-approved injectable pentosan product for this indication. Targeted at veterinary pharmaceutical companies and equine veterinary practices.
• Melarsomine Dihydrochloride (Diroban) FDA-approved generic drug (Melarsomine Dihydrochloride, brand: Diroban) for parasitic heartworm disease in dogs. The first generic drug approved for this veterinary indication. Targeted at veterinary pharmaceutical companies and canine veterinary practices.
• SENT008 Proprietary product candidate in preclinical development for the treatment of osteoarthritis in humans; available for licensing and commercialization partnerships.
• SENT012

Quantifiable outcome

• FDA inspected every 2 years since 2015 with continued compliance and good standing
• +2 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• API Innovation Center (APIIC)coreStrategic or Co-development PartnerAPIIC is a nonprofit working to modernize US pharmaceutical manufacturing by covering upfront capital costs for manufacturers adopting continuous production technologies. Sentio is working with APIIC on two additional active pharmaceutical ingredients, with the goal of proving that removing upfront financial barriers can enable safer and more efficient domestic production. In December 2024, APIIC awarded a contract to Sentio to advance development of two critical APIs.
• BioMap ConsortiumcoreStrategic or Co-development PartnerFlavia D'Souza, Co-Founder and Head of Quality at Sentio, was elected to the BioMap Consortium Executive Steering Committee in September 2024. BioMap is a consortium focused on pharmaceutical manufacturing innovation.
• MCDC-CBRNminorStrategic or Co-development PartnerConsortium member focused on medical countermeasures and chemical, biological, radiological, and nuclear defense.
• RRPVminorStrategic or Co-development PartnerConsortium member focused on pharmaceutical manufacturing resilience.
• CortexminorStrategic or Co-development PartnerSt. Louis-based innovation hub supporting workforce development and biotech ecosystem.
• BioSTLminorStrategic or Co-development PartnerSt. Louis-based organization supporting bioscience innovation and economic development.
• Apertus PharmaceuticalscoreStrategic or Co-development PartnerManufacturing partner collaborating with API Innovation Center on pharmaceutical production. Apertus operates the Missouri facility where lomustine manufacturing is being modernized.
• UMSLminorOthersUniversity of Missouri-St. Louis - academic partnership for workforce development and research collaboration.
• Missouri S&TminorOthersMissouri University of Science and Technology - academic partnership for workforce development and research.
• SLUminorOthersSaint Louis University - academic partnership for research and talent development.
• Washington University in St. LouisminorOthersWashington University - academic partnership for research collaboration and innovation.

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights8 records

Customer concentration

• LinkedInlinkedin.com/company/sentio-biosciences-llc

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sentio BioSciences